Page last updated: 2024-08-21

pyrazines and plx4032

pyrazines has been researched along with plx4032 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ	1
Bantscheff, M; Bergamini, G; Gohlke, B; Gupta, V; Handa, H; Heinzlmeir, S; Helm, D; Klaeger, S; Kuster, B; Médard, G; Perrin, J; Preissner, R; Qiao, H; Savitski, MM	1

Other Studies

2 other study(ies) available for pyrazines and plx4032

Article	Year
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib	2014
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors. ACS chemical biology, 2016, 05-20, Volume: 11, Issue:5 Topics: Benzocycloheptenes; Cell Line, Tumor; Ferrochelatase; Heme; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Proteomics; Pyrazines; Pyridines; Quinolines; Sulfonamides; Vemurafenib	2016

Article

Year

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib

2014

Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.

ACS chemical biology, 2016, 05-20, Volume: 11, Issue:5

Topics: Benzocycloheptenes; Cell Line, Tumor; Ferrochelatase; Heme; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Proteomics; Pyrazines; Pyridines; Quinolines; Sulfonamides; Vemurafenib

2016